Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 1 2Phase 3 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 43Waldenstrom Macroglobulinemia 4Recurrence 4Lymphoma, Mantle-Cell 3Lymphoma 3Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Plasmacytoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Genetic Diseases, Inborn 1Congenital Abnormalities 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 58Dexamethasone 50Rituximab 39Peripheral Blood Stem Cell Transplantation 29Paclitaxel 29Lenalidomide 28fludarabine phosphate 27Gemcitabine 26Etoposide 26Bortezomib 26Cytarabine 25Busulfan 24pembrolizumab 21Radiotherapy 21Bevacizumab 21Carboplatin 20Mycophenolic Acid 19Melphalan 19Cisplatin 19Filgrastim 18pomalidomide 17fludarabine 17Oxaliplatin 17Antilymphocyte Serum 17Cyclosporine 16Tacrolimus 15Methotrexate 15Whole-Body Irradiation 14Methylprednisolone 13Bendamustine Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Recurrence × ixazomib × Clear all
NCT02461888 2025-12-17

MUKEight

University of Leeds

Phase 2 Completed
112 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03683277 2025-02-19

IFM2014-01

Intergroupe Francophone du Myelome

Phase 2 Terminated
26 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

NCT02499081 2021-06-11

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

University of Arkansas

Phase 2 Completed
20 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

University of Arkansas

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡